Eli Lilly and Company (NYSE:LLY) Shares Down 2.7% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY)’s share price fell 2.7% on Monday . The company traded as low as $1,144.43 and last traded at $1,146.90. 2,632,708 shares changed hands during mid-day trading, a decline of 17% from the average session volume of 3,177,944 shares. The stock had previously closed at $1,179.11.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor interest remains strong in Eli Lilly’s weight-loss and diabetes pipeline, with media coverage highlighting the company as a key way to play the high-growth obesity-drug market. Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?
• Positive Sentiment: Lilly is one of the most watched stocks on Zacks, suggesting traders are actively positioning ahead of potential catalysts and expecting continued momentum. Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
• Positive Sentiment: Analysts and investors continue to view Lilly as a major beneficiary of the broader obesity-treatment boom, keeping the long-term growth story intact. Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on LLY shares. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Bank of America boosted their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Finally, Wolfe Research reissued an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,283.64.

Eli Lilly and Company Stock Down 2.7%

The firm has a market cap of $1.08 trillion, a price-to-earnings ratio of 40.74, a P/E/G ratio of 1.48 and a beta of 0.51. The firm has a 50 day moving average price of $1,118.87 and a 200-day moving average price of $1,036.51. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period last year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 34.55 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently bought and sold shares of LLY. Ballast Inc. grew its holdings in Eli Lilly and Company by 10.9% during the 2nd quarter. Ballast Inc. now owns 4,427 shares of the company’s stock valued at $5,310,000 after buying an additional 434 shares during the last quarter. Regent Peak Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company by 4.2% in the second quarter. Regent Peak Wealth Advisors LLC now owns 2,995 shares of the company’s stock worth $3,592,000 after acquiring an additional 120 shares during the last quarter. Northside Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 3.0% in the second quarter. Northside Capital Management LLC now owns 20,894 shares of the company’s stock worth $25,061,000 after acquiring an additional 618 shares during the last quarter. Annex Advisory Services LLC lifted its position in shares of Eli Lilly and Company by 1.6% in the second quarter. Annex Advisory Services LLC now owns 3,835 shares of the company’s stock valued at $4,599,000 after acquiring an additional 60 shares in the last quarter. Finally, Insight Wealth Strategies LLC increased its position in Eli Lilly and Company by 5.8% during the 2nd quarter. Insight Wealth Strategies LLC now owns 273 shares of the company’s stock worth $325,000 after purchasing an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.